________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Cosentyx (secukinumab) in Rheumatology [2]

Cosentyx is the first and only fully human targeted IL-17A inhibitor that offers fast and lasting relief from the signs and symptoms of PsA* and axSpA^†‡

Cosentyx_WhyCosentyx_HCP_1

Cosentyx_WhyCosentyx_HCP_2

Cosentyx_WhyCosentyx_HCP_3

Find out more using the links below...

[3]

[4]

* [5]

Footnotes

*Patients with PsA receiving Cosentyx achieved significant improvement in ACR20 vs placebo at Week 24: 54% Cosentyx300 mg s.c.; 51% 150 mg s.c. vs 15% placebo P<0.0001.² This improvement was sustained after 5 years of treatment.³
^†Patients with AS receiving Cosentyx achieved significant improvement in ASAS20 vs placebo at Week 16: 61% Cosentyx 150 mg s.c. vs 28% placebo (P<0.001).⁵ This improvement was sustained after 5 years of treatment.⁶
^‡Patients (NSAID-IR) with nr-axSpA receiving Cosentyx 150 mg s.c. vs placebo (N=555). Primary endpoint was met: ASAS40 at Week 16 and Week 52. ASAS40 vs placebo at Week 16: 42% Cosentyx 150 mg s.c. vs 29% placebo (P<0.05). This improvement was sustained after 1 year of treatment.⁷
^δPatients with active AS receiving Cosentyx 150 mg (n=54 at Year 5).⁶
^§Not limited to licensed indications.
**Across all licensed indications.

Abbreviations

ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS, Assessment in SpondyloArthritis international Society; axSpA, axial spondyloarthritis; BAD, British Association of Dermatologists; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism IL, interleukin; ISR, injection site reaction; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis; s.c. subcutaneous; TB, tuberculosis.

References

Cosentyx SmPC Available at www.medicines.ie [6] last accessed March 2023
McInnes IB et al. Lancet. 2015;386:1137–46.
McInnes IB et al. Lancet Rheumatol. 2020;2:e227–35.
Rheumatology DOF UK 102.
Baeten D et al. N Engl J Med. 2015;373:2534–48.
Marzo-Ortega H et al. Lancet Rheumatology. 2020;2:e339–46.
Deodhar A et al. Arthritis Rheumatol. 2020 (epub ahead of print).
Reich K et al. Br J Dermatol. 2019;181:954–66.
Thaci D et al. J Am Acad Dermatol. 2015;73:400–9.
Baraliakos X et al. Ann Rheum Dis. 2019;78. Abstract OP0235.
McInnes IB et al. Lancet Rheumatol. 2020;2(4):e227-e235
Baraliakos X et al. RMD Open. 2019;5(2):e001005.
Braun J et al. Rheumatology (Oxford). 2019;58:859–68.
Deodhar A et al. Ann Rheum Dis. 2020;79:722.
Langley RG et al. N Engl J Med. 2014;371:326–38.
McInnes IB et al. Lancet 2020;395:1496–505.
Yiu Z et al. Br J Dermatol. 2020;183:294–302.
Novartis Data on File. Secukinumab Cumulative Patient Numbers, Sec008. Feb 2023
ClinicalTrials.gov. A study comparing AIN457 to placebo in subjects with a diagnosis of moderate to severe stable plaque psoriasis. https://clinicaltrials.gov/ct2/show/NCT00669916 [7]. Accessed 20 March 2023.
Novartis Cosentyx^® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis [press release]. Basel, Switzerland. 17 September 2019. Novartis Cosentyx^® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis | Novartis Accessed 23 March 2023
Novartis Q1 2022 Earnings. Available at: Q1 2022 Results (novartis.com [8]) Accessed April 2022.